Clinical trial NCT02283359: Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
Official title: An Investigator Sponsored Phase 1a/1b Trial of Selinexor in Combination With Irinotecan in Patients With Adenocarcinoma of Stomach and Distal Esophagus
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Esophageal Cancer
Gastric Cancer
Keywords: Distal Esophagus
Esophageal
Gastric
Carcinoma
Adenocarcinoma
Stomach
Gastro-esophageal junction
Recurrent
Metastatic
Unresectable
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
First posted: 2014-11-05
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer. Researchers also want to find out if the combination of selinexor (KPT-330) and irinotecan is safe and tolerable.

Detailed description: This is an open label, single group, non-randomized, phase I study with cohort expansion that utilizes the standard 3+3 design for dose. The dose of selinexor will be escalated in combination with the standard doses of irinotecan. The maximum tolerated dose (MTD) for study is defined as the highest dose level at which 1 or less of 6 patients experience a dose limiting toxicity DLT.

Once the MTD is reached and/or the recommended dose for expansion is determined, an additional cohort of 15 patients with advanced gastric or esophageal cancer will be accrued to better define the safety and tolerability of the combination regimen.

Eligibility criteria: Inclusion Criteria:

* Must have histologically confirmed gastric, gastro-esophageal junction or distal esophageal adenocarcinoma (predominant histology) that is recurrent, metastatic or unresectable
* Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
* Must have received at least one line but less than three lines of prior systemic therapies and have either progressed or intolerant to prior therapies. Patients who have received adjuvant/neoadjuvant therapy within last one year will be eligible as well.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤1
* Life expectancy of greater than 3 months
* Must have normal organ and marrow function
* Women of child-bearing potential (WOCBP) must agree to use dual methods of contraception and have a negative serum pregnancy test at screening. Male participants must use an effective barrier method of contraception if sexually active with a WOCBP. For both male and female participants, effective methods of contraception must be used throughout the study and for three months following the last dose.
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Have had chemotherapy, biologic therapy or radiotherapy within 3 weeks prior to entering the study
* Are receiving any other investigational agents for anti-cancer treatment within 3 weeks of starting study medication
* Symptomatic central nervous system (CNS) metastases
* Progression on irinotecan containing regimen
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan
* Major surgery within 2 weeks before cycle 1 Day 1 (C1D1)
* Unstable cardiovascular function
* Patients who are pregnant or lactating
* Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study.
* Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen)
* Any underlying condition that would significantly interfere with the absorption of an oral medication
* \> Grade 2 peripheral neuropathy at baseline
* Serious psychiatric or medical conditions that could interfere with treatment
* Concurrent therapy with approved or investigational anticancer therapeutic other than steroids
* History of gastrointestinal perforation and/or fistulae within 6 months prior to C1D1
* Use of strong CYP3A4 inducers or inhibitors within 2 weeks of starting study medication

Primary outcomes:
measure: Maximum Tolerated Dose (MTD)
timeFrame: Up to 18 months
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Up to 18 months
measure: Objective Response Rate (ORR)
timeFrame: Up to 18 months
measure: Best Overall Response
timeFrame: Up to 18 months
measure: Overall Survival (OS)
timeFrame: Up to 18 months
Other outcomes:
Locations:
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center and Research Institute
state: Florida
Study officials:
affiliation: H. Lee Moffitt Cancer Center and Research Institute
name: Amit Mahipal, M.D.
role: PRINCIPAL_INVESTIGATOR
References: